Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New DNA test could speed up fungal infection diagnosis in cancer patients

NCT ID NCT03349931

Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new DNA test called the MycoGenie kit to see how well it can diagnose invasive aspergillosis, a serious fungal infection, in 350 blood cancer patients. The test looks for the fungus's DNA in blood samples and can also detect drug resistance. The goal is to find a faster, more accurate way to diagnose this infection in high-risk patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

350 people

The number who actually took part.

Started

Feb 2018

Finished

Jan 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Hematological patients at high risk for invasive aspergillosis, who can be classified according to EORTC criteria

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult Patients (≥ 18 years) hospitalized in onco hematologic unit or in hematopoietic stem cell transplantation (HSCT) unit 2. Patients with acute leukemia undergoing induction for AML, ALL, chimotherapy with neutopenia \>10 days or Patients undergoing allogeneic stem cell chemotherapy transplantation 3. Patients with biweekly screening for GM detection in serum Exclusion Criteria: 1. Patient \< 18 years-old (minor) 2. Informed consent not available 3. Patient without affiliation to French social insurance 4. Patient without biweekly screening for GM detection in serum

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Invasive aspergillosis in patients with onco-haematological diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aspergillosis invasive aspergillosis leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Invasive aspergillosis in patients with onco-haematological diseases

Contacts and locations

Locations

  • CHRU de Lille, Hôpital Claude Huriez

    Lille, 59000, France

  • CHU Bordeaux, Groupe hospitalier

    Bordeaux, 33000, France

  • CHU de DIJON, Hôpital du bocage

    Dijon, 21000, France

  • CHU de Nantes, Hôpital de Moncousu

    Nantes, 44000, France

  • CHU de RENNES, hôpital de Pontchaillou

    Rennes, 35000, France

  • Hôpital Necker - Enfants maladies (AP-HP)

    Paris, Paris, 75015, France